EX-4.13 6 dex413.htm RESEARCH AND COLLABORATION AGREEMENT RESEARCH AND COLLABORATION AGREEMENT BY AND BETWEEN NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. AND EVOTEC (UK) LTD. Portions of this Exhibit were omitted and have been filed separately with the...Research and Collaboration Agreement • May 5th, 2020 • New York
This Research and Collaboration Agreement (this “Agreement”) is made and entered into as of this 30th day of October (the “Effective Date”), by and between Evotec (UK) Ltd., a corporation organized and existing under the laws of England, with its principal offices at Abingdon, Oxford, OX14 4SA, UK (“Evotec”), and Novartis International Pharmaceutical Ltd., a Bermuda corporation with principal offices at 131 Front Street, Hamilton, Bermuda (“Novartis”).
AMENDED AND RESTATED RESEARCH AND COLLABORATION AGREEMENT by and among Eli Lilly and Company and ProQR Therapeutics N.V. and ProQR Therapeutics VIII B.V. AMENDED AND RESTATED RESEARCH AND COLLABORATION AGREEMENTResearch and Collaboration Agreement • December 23rd, 2022 • ProQR Therapeutics N.V. • Pharmaceutical preparations • New York
This Amended and Restated Research and Collaboration Agreement (“Agreement”) entered into as of December 21st, 2022 (the “A&R Effective Date”), by and among ProQR Therapeutics N.V., a company organized and existing under the laws of the Netherlands, having its principal place of business at Zernikedreef 9, 2333 CK Leiden, The Netherlands, and ProQR Therapeutics VIII B.V., a company organized and existing under the laws of the Netherlands, having its principal place of business at Zernikedreef 9, 2333 CK Leiden, the Netherlands, (such entities, collectively, “ProQR”), and Eli Lilly and Company, a corporation organized and existing under the laws of Indiana, with its principal business office located at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A. (“Lilly”), amends, restates and supersedes in its entirety (except as expressly set forth herein), that certain Research and Collaboration Agreement, entered into as of September 3rd, 2021 (the “Effective Date”), by and among the
RESEARCH AND COLLABORATION AGREEMENTResearch and Collaboration Agreement • March 13th, 2012 • Champions Oncology, Inc. • Biological products, (no disgnostic substances) • Delaware
This Research and Collaboration Agreement (“Agreement”) is effective as of March 16, 2011 (the “Effective Date”) between Cephalon, Inc., a Delaware corporation with offices located at 41 Moores Road, Frazer, Pennsylvania 19355 (“Cephalon”) and Champions Biotechnology, Inc., a Delaware corporation with offices located at 855 N. Wolfe Street, Suite 619, Baltimore, Maryland 21205 (“Champions”).
RESEARCH AND COLLABORATION AGREEMENT BETWEEN JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO., LTD AND ARRIVENT BIOPHARMA, INC. June 2, 2024Research and Collaboration Agreement • August 14th, 2024 • ArriVent BioPharma, Inc. • Pharmaceutical preparations
This RESEARCH AND COLLABORATION AGREEMENT (this “Agreement”) is made and entered into on June 2, 2024 (the “Effective Date”), by and between JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO., LTD, with a place of business at No. 175 Fangzhou Road, SIP, Suzhou, Jiangsu, P.R. China 215125 (“Alphamab”), and ARRIVENT BIOPHARMA, INC., with a place of business at 18 Campus Blvd, Suite 100, Newtown Square, PA 19073-3269, United States (“ArriVent”). Alphamab and ArriVent may be referred to herein individually as a “Party” and collectively as the “Parties.”
ContractResearch and Collaboration Agreement • January 6th, 2022
Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications
PURSUANT TO ITEM 601(B)(2)(II) OF REGULATION S-K, CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS AS [****], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR...Research and Collaboration Agreement • February 3rd, 2022 • RenovaCare, Inc. • Surgical & medical instruments & apparatus • New York
Research and Collaboration Agreement is made as of the 28 day of January, 2022 (the “Effective Date”) by and between RenovaCare Inc, a Nevada corporation, having an executive office is at 9375 E. Shea Blvd., Suite 107-A, Scottsdale, AZ 85260 (USA) (the “RCAR”) and HistoCell S.L., a regenerative medicine company, having offices at Parque Tecnologico 801. 2nd Floor, 48160 – Derio (Bezkaia) Spain, (“HistoCell”) (this “Agreement”); each of RCAR and HistoCell are also referred to individually herein as a “Party” or collectively as the “Parties.”
6 DC_DOCS\84421.8 RESEARCH, COLLABORATION AND DISTRIBUTION AGREEMENT This Agreement is made and entered into the 22nd day of December, 1997, by and between PerImmune, Inc., a Delaware corporation ("PERIMMUNE"), maintaining an office at 1330 Piccard...Research and Collaboration Agreement • August 14th, 1998 • Mentor Corp /Mn/ • Orthopedic, prosthetic & surgical appliances & supplies • Maryland
RESEARCH AND COLLABORATION AGREEMENT between TEVA PHARMACEUTICAL INDUSTRIES LIMITED and COCRYSTAL DISCOVERY, INC. Dated as of September 13, 2011Research and Collaboration Agreement • August 14th, 2014 • Cocrystal Pharma, Inc. • Pharmaceutical preparations • New York
THIS RESEARCH AND COLLABORATION AGREEMENT (the “Agreement”) is made and entered into as of September 13, 2011 (“Effective Date”) by and between:
Research and Collaboration AgreementResearch and Collaboration Agreement • May 4th, 2023
[«AgreementPartyName_1»], a corporation incorporated under the laws of [Canada][Ontario] having its administrative offices at [insert address] (“Company”)
RESEARCH AND COLLABORATION AGREEMENTResearch and Collaboration Agreement • August 10th, 2023 • Verve Therapeutics, Inc. • Pharmaceutical preparations • New York
This Research and Collaboration Agreement (this “Agreement”) is made and entered into as of June 14, 2023 (the “Execution Date”) by and between Verve Therapeutics, Inc., a Delaware corporation (“Verve”), and Eli Lilly and Company, an Indiana corporation (“Lilly”). Verve and Lilly are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Dated July 11th 2014 BIOMICS BIOTECH CO., LTD. and BENITEC BIOPHARMA LIMITED RESEARCH AND COLLABORATION AGREEMENT- OVERALL PROJECT FRANCIS ABOURIZK LIGHTOWLERS Commercial & Technology Lawyers Level 16 MELBOURNE VIC 3000 Tel: (03) 9642 2252 Fax: (03)...Research and Collaboration Agreement • June 22nd, 2015 • Benitec Biopharma LTD/ADR • Pharmaceutical preparations
Biomics Biotech Co., Ltd. (Chinese Registration Number 320600400015467) of 76 Changxing Rd, Economic & Technology Development Area, Nantong 226016 P.R. China (“Biomics”)
